false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Onconep ...
Is It Real? AKI and Electrolyte Disturbances in Ca ...
Is It Real? AKI and Electrolyte Disturbances in Cancer and Novel Targeted Therapies
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The talk reviewed kidney and electrolyte complications of molecularly targeted cancer therapies. Many drugs cause an early creatinine rise by inhibiting proximal-tubule creatinine secretion, but true kidney injury can coexist; biopsies most often show acute tubular injury. Creatinine alone cannot distinguish pseudo-AKI from nephrotoxicity. Clinicians should assess cystatin C, urine findings, measured GFR when available, and consider biopsy for persistent unexplained decline, while interpreting changes in light of each drug’s mechanism.<br /><br />The presentation also highlighted characteristic electrolyte effects: imatinib-related hypophosphatemia from altered bone-mineral metabolism, cetuximab-related renal magnesium wasting with secondary hypokalemia and hypocalcemia, and tumor lysis syndrome with venetoclax. Targeted therapies can also cause other true or pseudo-electrolyte abnormalities.<br /><br />Although some drug groups are associated with later kidney-function decline, an initial creatinine rise did not reliably predict it. The key clinical goal is to identify and manage complications without unnecessarily interrupting effective cancer treatment, in partnership with oncology.
Asset Caption
Susan Ziolkowski, MD, MS, FASN
Meta Tag
Speaker
Susan Ziolkowski
Keywords
kidney complications
electrolyte abnormalities
targeted cancer therapy
pseudo-AKI
acute tubular injury
creatinine rise
×
Please select your language
1
English